目的：评价Ahmed青光眼引流阀植入术及雷珠单抗治疗新生血管型青光眼的疗效。

方法：新生血管型青光眼(NVG)患者80例80眼，按治疗方法不同分为对照组(34例34眼)和研究组(46例46眼)。对照组采用Ahmed青光眼引流阀植入术治疗，研究组采用Ahmed青光眼引流阀植入术联合雷珠单抗注射液治疗，比较两组患者临床疗效、眼压、视力和并发症发生情况。

结果：术后6mo，研究组手术总成功率高于对照组(P<0.05)。术前4d两组眼压比较无差异(P>0.05)，术后7d两组患者眼压均下降，且研究组低于对照组(P<0.05)。术后6mo，研究组视力提高率高于对照组(P<0.05)。随访6mo内，研究组引流管阻塞、前房出血率低于对照组(P<0.05)，两组患者角膜水肿、前房渗出、眼球疼痛、浅前房和低眼压率比较无差异(P>0.05)。

结论：Ahmed青光眼引流阀植入术联合雷珠单抗注射液能够合理控制眼压，改善患者视功能，是NVG患者安全、有效的治疗方案。

METHODS: Totally 80 patients(80 eyes)of neovascularization glaucoma(NVG)according to random number table method were divided into 34 cases(34 eyes)of control group and 46 cases(46 eyes)of research group, the control group was treated with Ahmed glaucoma drainage valve implantation, the research group was treated with Ahmed glaucoma valve implantation combined with rezuzumab, clinical curative effect, cytokines, intraocular pressure, vision after 6mo, and complications in both group were compared.

RESULTS: Six months after surgery, the total success rate of operation in the research group was higher than that in the control group(P<0.05). 4d before surgery, there were no significant differences in intraocular pressure between the two groups(P>0.05). 7d after surgery, intraocular pressure in both groups all decreased, and the research group was lower than that in the control group(P<0.05). 6mo after surgery, the improvement rate of vision in the research group was higher than that in the control group(P<0.05). Within 6mo of follow-up, the drainage tube obstruction and hyphema rate in the research group were lower than those in the control group(P<0.05). There was no difference in corneal edema, anterior chamber exudation, eyeball pain, shallow anterior chamber and low intraocular pressure rate between the two groups(P>0.05).

CONCLUSION:Ahmed glaucoma drainage valve implantation combined with rezumab injection can reasonably control intraocular pressure and improve visual function of patients. It is a safe and effective treatment scheme for NVG patients.